NHI-2 (50-200 μM, 8 h) inhibits lactate production in HeLa cells [1].
NHI-2 (12-40 μM, 72 h) inhibits the proliferation of B78 cells [2].
The EC50 of NHI-2 (0.1-100 μM, 48 h) on B78 cells was 32 μM [2].
The combination of NHI-2 (40 μM, 24 h) with 30 or 60 mM Oxamate (Oxa) (HY-W013032A) enhances apoptosis [2].
NHI-2 (40 μM, 24 h) induces cell cycle arrest at the S/G2 phase [2].
NHI-2 affects extracellular acidification rate (ECAR) (12-26 μM, 80 min) and ATP (18 μM, 24 h) production, and synergizes with Oxa [2].
As a competitive inhibitor of NADH, NHI-2 not only affects glycolysis but also influences mitochondrial metabolism and the NAD+/NADH balance [2].
Cell Viability Assay
| Cell Line: |
B78-D14 melanoma cells |
| Concentration: |
0.1-100 μM |
| Incubation Time: |
48 hours |
| Result: |
The EC50 values of 32 μM. |
Cell Proliferation Assay
| Cell Line: |
B78-D14 melanoma cells |
| Concentration: |
12, 18, 26, 40, μM |
| Incubation Time: |
72 hours |
| Result: |
Exhibited no effect on B78 cell proliferation at lower concentrations. but decreased cell proliferation at concentrations beginning from 26 μM. |
Apoptosis Analysis
| Cell Line: |
B78-D14 melanoma cells |
| Concentration: |
40 μM |
| Incubation Time: |
24 hours |
| Result: |
Increased cell apoptosis when combined with either 30 or 60 mM Oxa |
Cell Cycle Analysis
| Cell Line: |
B78-D14 melanoma cells |
| Concentration: |
40 μM |
| Incubation Time: |
24 hours |
| Result: |
Led to an increased cell population in the S and G2 phases. |